Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New app and MRI tool aim to improve MS care

NCT ID NCT05949580

Knowledge-focused Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study tests a digital platform that combines an app for patients and a brain-scan analysis tool for doctors. The goal is to see if it helps monitor multiple sclerosis (MS) more easily in everyday care. About 500 people with relapsing-remitting MS will use the app and have their MRI scans analyzed by the platform over two years. Researchers will ask doctors and patients how user-friendly and helpful the platform is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MS Care Platform (icobrain ms and icompanion ms)
What this could lead to
If successful, this platform could give doctors better tools to track MS progression and adjust treatments more quickly.
What could go wrong
This is an early-stage usability study, not a treatment trial. It measures how well doctors and patients like the platform, not whether it improves health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with MS are enrolled in this study. Participants with RRMS were chosen because most available disease modifying therapies (DMTs) are approved for this subgroup, and hence guiding care in this population is most relevant.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to comply with the study protocol, including having a smartphone and being able and willing to access the icompanion ms patient app on a regular basis. To use all functionalities of the icompanion ms patient app, the user's smartphone must comply with the minimum system requirements (Android version 5.0 or above, iOS version 11 or above) * Have a valid email address (for registration of icompanion ms) * Have a definite diagnosis of RRMS * Time since MS diagnosis ≥1 year * Medical history recorded for at least 1 year before enrollment * Expanded Disability Status Scale (EDSS) \<5.5 Exclusion Criteria: * Any contra-indications to using icompanion ms patient app or website, as per the investigator's discretion * Inability to complete an MRI * Currently involved in an interventional trial * Diagnosis of progressive MS (primary progressive multiple sclerosis \[PPMS\] or secondary progressive multiple sclerosis \[SPMS\])

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsing-remitting multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsing-remitting multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • Hospital General Universitario Dr. Balmis

    Alicante/alacant, Alicante, 03010, Spain

  • Hospital Universitario de Gran Canaria

    Las Palmas, 35010, Spain

  • Jersey Shore University Medical Centre

    Neptune City, New Jersey, 07753, United States

  • Minneapolis Clinic of Neurology

    Golden Valley, Minnesota, 55422, United States

  • Praxis Dr. med. Max Deist und Michael Ernst ?Sinsheim

    Sinsheim, 74889, Germany

  • Universitaetsklinikum Carl Gustav Carus an der TU Dresden

    Dresden, 01307, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.